New hair loss pill shows promise in early trial
NCT ID NCT06527365
First seen Jun 24, 2026 · Last updated Jun 24, 2026
Summary
This Phase 2 study tests an investigational oral drug called VDPHL01 in 70 adults with mild to moderate pattern baldness. Participants take a tablet once or twice daily for 12 months. Researchers will measure changes in hair count and ask participants about perceived benefit. The goal is to see if the drug is safe and effective for treating genetic hair loss.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANDROGENETIC ALOPECIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
01
San Diego, California, 92123, United States
-
02
South Jordan, Utah, 84095, United States
-
03
Hackensack, New Jersey, 07601, United States
-
04
New Albany, Indiana, 47150, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
VDPHL01 (an oral tablet)
What this could lead to
If successful, this could lead to a new daily pill to treat male and female pattern baldness.
What could go wrong
This is an early Phase 2 open-label study with only 70 people, so results may not apply broadly. The drug is still investigational and may not prove effective or safe in larger trials.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.